NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$113.66 +2.86 (+2.58 %)
(As of 01/17/2019 04:00 PM ET)
Previous Close$110.80
Today's Range$110.16 - $114.80
52-Week Range$51.05 - $133.74
Volume537,600 shs
Average Volume499,658 shs
Market Capitalization$3.32 billion
P/E Ratio-7.90
Dividend YieldN/A
Beta-0.68
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130.96 million
Book Value$0.65 per share

Profitability

Net Income$-360,360,000.00
Net Margins-202.93%

Miscellaneous

Employees507
Market Cap$3.32 billion
OptionableOptionable

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced its quarterly earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, beating analysts' consensus estimates of ($2.65) by $0.47. The biopharmaceutical company earned $47 million during the quarter, compared to analysts' expectations of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. Intercept Pharmaceuticals's quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.89) earnings per share. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Intercept Pharmaceuticals.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2018 earnings guidance on Wednesday, October, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $170-185 million, compared to the consensus revenue estimate of $181.84 million.

What price target have analysts set for ICPT?

18 brokerages have issued 1 year price targets for Intercept Pharmaceuticals' shares. Their forecasts range from $57.00 to $253.00. On average, they expect Intercept Pharmaceuticals' share price to reach $158.1333 in the next twelve months. This suggests a possible upside of 39.1% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC.  Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. Solid growth in new patient enrollment in the third-quarter should lead to stronger sales in the fourth quarter. Moreover, the company is looking to expand the drug’s label in the promising NASH  and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Results from the REGENERATE trial are expected in the first quarter of 2019. However, we are concerned about the lack of other late-stage candidates in the company’s pipeline. Shares have outperformed the industry in the last six months." (1/16/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $170 12-month price target. We think Elafibranor Ph2 PBC data from Genfit (GNFT.PA, Not covered) looks competitive among Ph2 assets but we do not view today’s update as a near or mid-term threat to ICPT’s OCA. Elafibranor Ph2 looks broadly similar to recently updated Sedalapar data (for 52-week analysis) from Cymabay (CBAY, OW E. Merle) which is not surprising as both are PPAR agonists, but detailed full data could be helpful in comparing the efficacy and safety profiles of these assets. We think pivotal PBC trial enrollment will take time before either asset would pose a commercial threat to OCA in PBC. We remain focused on REGENERATE readout in NASH for ICPT in 1H 2019." (12/6/2018)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

Media headlines about ICPT stock have been trending negative on Thursday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future.

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Mark E. Pruzanski, President, Chief Executive Officer & Director
  • Jerome B. Durso, Chief Operating Officer
  • Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer
  • David A. Shapiro, Chief Medical Officer
  • Christian Weyer, Executive Vice President-Research & Development

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.36%) and Virtu Financial LLC (0.02%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim, Sandip Kapadia and SPA Genextra. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Virtu Financial LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $113.66.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $3.32 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  874 (Vote Outperform)
Underperform Votes:  483 (Vote Underperform)
Total Votes:  1,357
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel